Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Michael Sullivan-MeeClifford Qualls

Abstract

To investigate hypersensitivity rates in patients switched from brimonidine-purite 0.15% to generic brimonidine 0.2%, and to then investigate hypersensitivity rates to re-initiated brimonidine-purite 0.15% in patients who developed hypersensitivity to brimonidine 0.2%. Ocular hypersensitivity reactions to generic brimonidine 0.2% were identified by retrospective chart review after all Albuquerque Veterans Administration Medical Center patients taking brimonidine-purite 0.15% were switched to generic brimonidine 0.2% due to a facility formulary change. Because brimonidine-purite 0.15% was subsequently re-initiated in some patients who developed hypersensitivity to brimonidine 0.2%, hypersensitivity reactions to re-initiated brimonidine-purite 0.15% were also identified. Three hundred thirteen subjects met inclusion criteria for this study. Of these, 24 [7.7%; 95% confidence interval (CI): 5.0, 11.2] developed hypersensitivity to brimonidine 0.2% after being switched from brimonidine-purite 0.15%. Fifteen of these 24 patients were subsequently instructed to resume use of brimonidine-purite 0.15%; 3 of these 15 (20%; 95% CI: 4.3, 48.1) developed hypersensitivity to brimonidine-purite 0.15%. Our results suggest that the hypersensit...Continue Reading

References

May 20, 1999·American Journal of Ophthalmology·D H ShinK D Nguyen
Feb 28, 2002·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Pierre Blondeau, Jacques Armand Rousseau
Sep 12, 2002·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Andrew A AcheampongDiane Tang-Liu
Mar 22, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Tom MundorfAmy Batoosingh
Oct 24, 2003·The New England Journal of Medicine·Brian L StromDan Pettitt
Jun 29, 2004·Cornea·Robert J NoeckerRaana Anwaruddin
Aug 24, 2004·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jennifer Q DongScott M Whitcup
Aug 25, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·E Randy CravenUNKNOWN Combigan Study Group
Sep 1, 2005·Current Opinion in Allergy and Clinical Immunology·Christophe Baudouin
Mar 27, 2007·Neuroscience·S RutzR Jackisch
Jul 11, 2007·Experimental Dermatology·Husameldin El-NourKlas Nordlind
Sep 29, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Chan Yun KimGong Je Seong

❮ Previous
Next ❯

Citations

Apr 29, 2011·Experimental Eye Research·Stella Arthur, Louis B Cantor
Nov 9, 2018·Expert Opinion on Pharmacotherapy·Daniel J OhMark S Dikopf
Aug 9, 2011·Current Opinion in Allergy and Clinical Immunology·Flavio MantelliStefano Bonini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

© 2021 Meta ULC. All rights reserved